<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979483</url>
  </required_header>
  <id_info>
    <org_study_id>Urgence Pancreas D16-1</org_study_id>
    <nct_id>NCT02979483</nct_id>
  </id_info>
  <brief_title>Management of Symptomatic Advanced Pancreatic Adenocarcinoma</brief_title>
  <official_title>Management of Symptomatic Advanced Pancreatic Adenocarcinoma: &quot;Urgence Pancreas&quot; - A Prospective A.R.CA.D Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the feasibility and effects of an early integrative supportive care
      program in patient with Advanced pancreatic adenocarcinoma (aPDAC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two-step cohort study:

      * Step 1 : A 14-day integrative supportive care program initiated as early as the clinical
      suspicion of aPDAC.

      According to the investigator's assessment of patient needs, this integrative supportive care
      program will include:

        -  management of pain

        -  nutritional support

        -  pathologic diagnosis (endoscopy guides or percutaneous biopsies or ascitis cytology)

        -  diagnostic computed imaging

        -  endoscopic stenting of the bile duct and/or duodenum

           * Step 2 : Follow up after the integrative supportive care program. According to their
           Eastern Cooperative Oncology Group Performance Status(ECOG PS) and/or chemotherapy

        -  Group 1 : Patient becoming eligible for treatment with FOLFIRINOX or nab-paclitaxel +
           gemcitabine and / or clinical trial

        -  Group 2 :Patient at the end of the 14-day program (Step 1) remaining with either :

      a - Persisting ECOG PS ≥ 2

      b - Clinico-biological features that make them ineligible to receive the FOLFIRINOX or
      nab-paclitaxel + gemcitabine regimens

      c - Patient ineligible to other therapeutic clinical trial
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>STEP 1 : Success rate (feasibility + clinical benefit) of the 14-day integrative supportive care program</measure>
    <time_frame>14 days (+/- 2 days)</time_frame>
    <description>Success of the integrative supportive care program following the first medical appointment in patients who have evocative symptom or pathologically confirmed symptomatic Advanced pancreatic adenocarcinoma (aPDAC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STEP 2 : 3-month Overall Survival rate</measure>
    <time_frame>Up to 3 months after the beginning of the chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delay from first symptom of aPDAC to first medical appointment</measure>
    <time_frame>Up to 2-3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay from first medical appointment to beginning of chemotherapy</measure>
    <time_frame>Up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients improvement of ECOG PS and clinico-biologic parameters</measure>
    <time_frame>Up to 14-day</time_frame>
    <description>for biologic : livers tests, including bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients receiving chemotherapy</measure>
    <time_frame>At 14 days, at 21 days, Up to death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of chemotherapy administered</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>type of chemotherapy : FOLFIRINOX, nab-paclitaxel + gemcitabine, gemcitabine alone, FOLFOX7 light or only best supportive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients included in a clinical trial</measure>
    <time_frame>Up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison score of Health-related quality of life (HRQoL)</measure>
    <time_frame>Between the score of HRQoL before the program and the score of HRQoL at the end of the 14 days program</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patient included in each group</measure>
    <time_frame>up to two years (after the recruitment of all patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival in each group</measure>
    <time_frame>up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in each group</measure>
    <time_frame>up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of HRQoL (QLQ-C15 PAL)</measure>
    <time_frame>Month 1 and every two months up to two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Pancreas</condition>
  <condition>Management Supportive Care Program</condition>
  <arm_group>
    <arm_group_label>Integrative Supportive Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All planed procedures established during the first consultation with the investigator is successfully completed within the 14-day (+/-2 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Integrative supportive care</intervention_name>
    <description>At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)
At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:
Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.
Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial
- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.
Patients will be treated by: FOLFOX7lightened</description>
    <arm_group_label>Integrative Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - STEP 1:

          1. Pathologically confirmed or highly suspected aPDAC defined as a pancreatic mass on
             imaging, suspected distant metastases, no features suggestive of a neuroendocrine
             tumor, and/or clinico-biological abnormalities compatible with the diagnosis of aPDAC,

          2. Age ≥ 18 years,

          3. Patients with ECOG PS ≥ 2 and clinico-biological features precluding initial
             therapeutic clinical trial and/or treatment with FOLFIRINOX or gemcitabine +
             nab-paclitaxel,

          4. No prior history of cancer, except: in situ breast, cervix cancer, or basal cell
             carcinoma and/or complete remission for more than 3 years from another cancer.

          5. Registration in France with the French National Health Care System (CMU included)

          6. Patient able to comply with study protocol requirements in the view of the
             investigator,

          7. Before patient registration, written informed consent must be obtained according to
             ICH/GCP and national/local regulations,

          8. Patients requiring at least two components of the integrative care program (pain
             management, nutritional management, pathological assessment or imaging, and
             endoscopy/stent).

        Exclusion Criteria - STEP 1 :

          1. Any medical, psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial,

          2. Patient protected by law,

          3. Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoît ROUSSEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Henri Mondor Créteil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoît ROUSSEAU, MD</last_name>
    <email>benoit.rousseau@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe DEBOURDEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe DEBOURDEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal HAMMEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pascal HAMMEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît ROUSSEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoît ROUSSEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimery DE GRAMONT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aimery DE GRAMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christelle De la FOUCHARDIERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christelle de la FOUCHARDIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Layne</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérôme DAUBA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme DAUBA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grope Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric RAYMOND, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric RAYMOND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain CORIAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain CORIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Baptiste BACHET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Baptiste BACHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LOUVET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe LOUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux du Léman</name>
      <address>
        <city>Thonon les Bains</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed BEDJAOUI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ahmed BEDJAOUI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LECOMTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry LECOMTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

